US FDA orders new eye risk warnings for Ozempic, Zepbound

Reuters — 

The US Food and Drug Administration ‌on Monday informed patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes.

Read more Trump to meet with China’s Xi and Russia’s Putin at historic trilateral sit-down on nuclear non-proliferation

The FDA said it is requiring GLP-1 drugs such ​as Eli Lilly’s Mounjaro and Zepbound, and Novo Nordisk’s Ozempic and Wegovy to add information ​to the “warnings and precautions” section of labeling about the potential increased risk of non-arteritic ⁠anterior ischemic optic neuropathy (NAION).

“FDA’s drug safety communication applies to all medicines with GLP-1 RA activity and does ​not reference any findings specific to Lilly medicines. We are carefully evaluating the update and will respond to ​FDA promptly,” said a Lilly spokesperson.

The condition is a common cause of sudden, painless vision loss, and may lead to permanent impairment of sight in some cases. It is caused by decreased blood flow to the front part of the ​optic nerve, but the underlying cause is not completely understood.

“Novo continues to believe the data do not ​establish a cause-and-effect relationship and we remain confident in the benefit-risk profile of our GLP-1 medicines,” a spokesperson for Novo ‌said.

Related article
LOS ANGELES, CALIFORNIA - APRIL 17: In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, California. Ozempic was originally approved by the FDA to treat people with Type 2 diabetes- who risk serious health consequences without medication. In recent months, there has been a spike in demand for Ozempic, or semaglutide, due to its weight loss benefits, which has led to shortages. Some doctors prescribe Ozempic off-label to treat obesity. (Photo illustration by Mario Tama/Getty Images)
LOS ANGELES, CALIFORNIA – APRIL 17: In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, California. Ozempic was originally approved by the FDA to treat people with Type 2 diabetes- who risk serious health consequences without medication. In recent months, there has been a spike in demand for Ozempic, or semaglutide, due to its weight loss benefits, which has led to shortages. Some doctors prescribe Ozempic off-label to treat obesity. (Photo illustration by Mario Tama/Getty Images)
Mario Tama/Getty Images

Popular weight loss and diabetes drugs linked to increased risk of rare form of blindness

Read more After 26 years, the US has lost its measles elimination status

5 min read

The health ⁠regulator said it has evaluated clinical trial data, animal data, and post-marketing data, including observational studies and case reports.

“The FDA action may temporarily increase patient and investor concern, but the rarity of NAION and substantial weight, glycemic, cardiovascular, renal, and sleep apnea benefits should preserve a favorable benefit-risk profile and limit changes to ​prescribing,” Citi analyst Geoff ​Meacham said.

Last year, the ⁠European Medicines Agency’s safety committee said NAION may affect up to 1 in 10,000 people taking semaglutide, the active ingredient in Wegovy and Ozempic as well as ​in Novo’s other diabetes drug Rybelsus, for at least one year. That ​was the first ⁠time a regulator had confirmed the side effect.

Four patients in Denmark, who experienced vision loss after using Novo’s GLP-1 drugs, were granted compensation, the Danish Patient Compensation had said last year.

A large study published in 2025 tracked nearly 175,000 diabetic patients treated with semaglutide and an equal number taking non-GLP-1 medications. It ⁠found ​that the risk of NAION more than doubled ​after two years of treatment with a GLP-1 drug, compared to diabetes medicines from other classes.

Read more Inside Stephen Miller’s aggressive first week as Trump’s chief of staff

STREAMING NOW
1. All Access Horizontal with series logo_03.jpg
CNN

What losing weight on a GLP-1 does to your body

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *